Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of BCG-unresponsive high-risk non-muscle-invasive bladder cancer
4 evidence topics · 6 sources
Bladder cancer prevalence in the United States
Prevalent population eligible for treatment of BCG-unresponsive high-risk NMIBC, ICER estimate
Eligible population per 1 million health plan members, budget impact model estimate
Limits of classifying BCG-unresponsive disease in real-world data
“As a result, a substantial proportion of patients cannot be classified under existing criteria because the exposure-based and time-dependent conditions required by regulatory definitions are not met in routine practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Maintenance BCG is infrequently delivered, surveillance intervals vary widely, early radical cystectomy is limited by system-level and institutional factors, and key tumour-level variables required for classification are often missing in large-scale datasets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote